You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 12,013,403


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,013,403 protect, and when does it expire?

Patent 12,013,403 protects SPINRAZA and is included in one NDA.

This patent has five patent family members in four countries.


Recent additions to Drugs Protected by US Patent 12,013,403

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Biogen Idec SPINRAZA nusinersen sodium SOLUTION 209531 Dec 23, 2016 RX Yes ⤷  Subscribe ⤷  Subscribe U-1941 TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
Biogen Idec SPINRAZA nusinersen sodium SOLUTION 209531 Dec 23, 2016 RX Yes ⤷  Subscribe ⤷  Subscribe U-1942 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
Biogen Idec SPINRAZA nusinersen sodium SOLUTION 209531 Dec 23, 2016 RX Yes ⤷  Subscribe ⤷  Subscribe U-1943 TREATMENT OF SPINAL MUSCULAR ATROPHY
Biogen Idec SPINRAZA nusinersen sodium SOLUTION 209531 Dec 23, 2016 RX Yes ⤷  Subscribe ⤷  Subscribe U-1944 TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
Biogen Idec SPINRAZA nusinersen sodium SOLUTION 209531 Dec 23, 2016 RX Yes ⤷  Subscribe ⤷  Subscribe U-2093 TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
Biogen Idec SPINRAZA nusinersen sodium SOLUTION 209531 Dec 23, 2016 RX Yes ⤷  Subscribe ⤷  Subscribe U-2094 TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 12,013,403

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY ⤷  Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA ⤷  Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SPINAL MUSCULAR ATROPHY ⤷  Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE ⤷  Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY ⤷  Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,013,403

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112017004056 ⤷  Subscribe
Chile 2017000594 ⤷  Subscribe
Chile 2019000447 ⤷  Subscribe
Colombia 2017002400 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2016040748 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.